Business Segment Information (Tables)

9 Months Ended

Jun. 30, 2020

The following illustrates reportable and operating segment disaggregated revenue as required by Accounting Standards Codification 606 for the periods indicated:


	Three months ended June 30,						Nine months ended June 30,
(in thousands)	2020		2019		2020		2019
Pharmaceutical Distribution Services	$	43,579,119	$	43,527,552	$	135,178,617	$	128,948,097
Other:
MWI Animal Health	1,008,581		1,021,936		3,079,915		2,923,813
Global Commercialization Services	801,952		712,602		2,454,195		2,147,092
Total Other	1,810,533		1,734,538		5,534,110		5,070,905
Intersegment eliminations	(22,875)		(22,825)		(63,569)		(67,683)
Revenue	$	45,366,777	$	45,239,265	$	140,649,158	$	133,951,319

Segment operating income

The following illustrates reportable segment operating income for the periods indicated:


	Three months ended June 30,						Nine months ended June 30,
(in thousands)	2020		2019		2020		2019
Pharmaceutical Distribution Services	$	426,643	$	411,707	$	1,381,434	$	1,301,948
Other	82,875		95,110		295,614		293,923
Intersegment eliminations	(1,996)		(142)		(2,575)		(698)
Total segment operating income	$	507,522	$	506,675	$	1,674,473	$	1,595,173

Reconciliation of total segment operating income to income (loss) from operations before income taxes

The following reconciles total segment operating income to income before income taxes for the periods indicated:


	Three months ended June 30,						Nine months ended June 30,
(in thousands)	2020		2019		2020		2019
Total segment operating income	$	507,522	$	506,675	$	1,674,473	$	1,595,173
Gain from antitrust litigation settlements	—		3,480		8,546		142,735
LIFO (expense) credit	(6,061)		9,913		(43,195)		79,747
PharMEDium remediation costs	—		(19,344)		(16,165)		(55,736)
PharMEDium shutdown costs	(12,936)		—		(45,406)		—
New York State Opioid Stewardship Act	—		—		—		22,000
Contingent consideration adjustment	—		—		12,153		—
Acquisition-related intangibles amortization	(25,109)		(34,024)		(85,345)		(125,770)
Employee severance, litigation, and other	(58,585)		(60,006)		(165,626)		(156,067)
Impairment of PharMEDium assets	—		—		(361,652)		(570,000)
Operating income	404,831		406,694		977,783		932,082
Other loss (income), net	1,073		(342)		2,806		(11,739)
Interest expense, net	37,748		35,921		103,176		121,366

Loss on early retirement of debt	22,175		—		22,175		—
Income before income taxes	$	343,835	$	371,115	$	849,626	$	822,455